EOSINA AR SOL CUT 2% 100G

EOSINA NA 2% CUTANITY

active ingredients

100 g of solution contain Active ingredient: eosina 2 g Excipients with known effects: P-hydroxybenzoate sodium; Sodium p-hydroxybenzoate prototype For full list of excipients see paragraph 6.1

Excellent

- Excipient: purified water, methyl p-hydroxybenzoate sodium, propile p-hydroxybenzoate sodium.

Therapeutic indications

Local treatment for the disinfection of small superficial wounds, first-degree burns, insect bites, diaper erythitis, decubitate wounds with limited interest to the epidermis.

Contraindications

Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1.

Population

Apply 1- 2 times a day some drops, using a clean gauze or pour directly on the area to be treated; possibly cover with an appropriate dry sterile bandage.

Conservation

In well closed container, sheltered from light.

Warnings

Avoid application near the eyes. Eosina solution skin red color the skin; stains disappear in about three days. Important information about some excipients EOSINA NA 2% contains parahydroxybenzoates (P-hydroxybenzoate sodium; P-hydroxybenzoate sodium beads) that can cause allergic reactions (also delayed).

Interactions

There are no known interactions with other drugs.

Effects

Below are the undesirable effects of eosine, organized according to the organic classification MedDRA, with unknown frequency (the frequency of which cannot be established according to the available data). Immune system disorders Reactions of hypersensitivity Pathologies of skin and subcutaneous tissue Contact dermatitis Reporting of suspicious adverse reactions. The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Overdosing

There are no known toxic phenomena due to overdose.

Since systemic absorption is negligible, there are no predictable negative effects for the fetus during pregnancy and for the child during breastfeeding.

Source: Farmadati